https://assets.capyfin.com/instruments/678fdc13234e27009c5d5a57.png avatar
Waters
🇺🇸 NYSE:WAT
•
Dec 31, 2024

Waters Q4 2024 Earnings Report

Key Takeaways

Waters Corporation reported Q4 2024 sales of $873 million, reflecting a 6% increase year-over-year. GAAP EPS was $3.88, while non-GAAP EPS rose to $4.10, up 13%. Operating income stood at $292.26 million, and net income reached $231.40 million. Pharmaceutical market sales grew 10% in constant currency, with overall recurring revenue up 9%.

Total Revenue
$873M
Previous year: $819M
+6.5%
EPS
$4.1
Previous year: $3.62
+13.3%
Operating Margin
33.5%
Previous year: 32.2%
+4.0%
Pharmaceutical Market Sales
$499M
Previous year: $464M
+7.6%
Industrial Market Sales
$264M
Previous year: $260M
+1.5%
Gross Profit
$524M
Previous year: $489M
+7.2%
Cash and Equivalents
$325M
Previous year: $396M
-17.8%
Free Cash Flow
$188M
Previous year: $189M
-0.3%
Total Assets
$4.55B
Previous year: $4.63B
-1.6%

Waters Revenue

Waters EPS

Waters Revenue by Segment

Waters Revenue by Geographic Location

Forward Guidance

Waters Corporation expects full-year 2025 sales growth of 2.5%-5.0% as reported, with a constant currency growth of 4.5%-7.0%. Non-GAAP EPS is projected between $12.70-$13.00.

Positive Outlook

  • Full-year sales growth expected to be positive despite currency headwinds.
  • Strong pharmaceutical segment growth continues.
  • Recurring revenue remains a key driver of stability.
  • Operational efficiency improvements driving margin expansion.
  • New product adoption supporting revenue acceleration.

Challenges Ahead

  • Foreign exchange headwinds expected to reduce growth by 2%.
  • Industrial market growth remains relatively slow.
  • Potential macroeconomic challenges affecting customer spending.
  • Uncertainty in global regulatory environments.
  • Increased competition in analytical instruments sector.

Revenue & Expenses

Visualization of income flow from segment revenue to net income